• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Evolocumab demonstrated to have long-term efficacy at lowering low-density lipoprotiein: The Osler-1 trial

byAnees DaudandJames England
March 16, 2017
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This multi-year, open-label extension of phase 2 trials examining the LDL-lowering efficacy of evolocumab (PCSK9-inhibitor) showed that evolocumab plus standard of care lipid lowering therapy had continued lipid lowering response after over four years of follow-up.

2. Significant adverse events, including new-onset diabetes, neurocognitive complications, or development of neutralizing antibodies, were very uncommon in the study population and not increased compared to those receiving standard of care therapy.

Evidence Rating Level: 2 (Good)       

Study Rundown: Numerous trials have shown the efficacy of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9-inhibitor) at reducing low-density lipoprotein cholesterol (LDL-C) when statins were not sufficient. These trials, however, have only been studied over short periods, and none exceeded 24 months of follow-up. This study enrolled patients who had taken part in clinical trials for the PCSK9-inhibitor evolocumab to continue therapy in an open label trial to evaluate long term efficacy and safety.

This study demonstrated that evolocumab was associated with persistently low levels of LDL-C up to 4 years of follow-up both compared to standard-of-care (SOC) and prior baseline. Rates of significant adverse events did not differ between treatment and control arms, and development of new diabetes, neurocognitive deficits, or neutralizing antidrug antibodies were very low. The strengths of the study included large sample size, long follow up, and appropriate evaluation of possible adverse effects. Limitations of the study included the inherent bias of an open-label trial. Additionally, the trial enrolled patients who completed prior trials for evolocumab and thus excluded patients who had adverse events during the earlier trials. In addition, long term cardiovascular endpoints were not evaluated, which is the main outcome of concern.

Click to read the study, published in JAMA Cardiology

Relevant Reading: Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

RELATED REPORTS

No known association between PCSK9 gene variants and risk of heart failure

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

In-Depth [prospective cohort]: This study (Open-Label Study of Long-term Evaluation Against LDL-C, OSLER-1) was comprised of a cohort selected from phase 2 trials evaluating evolocumab therapy in patients with high risk of cardiovascular disease not receiving adequate lipid management with statin therapy. Patients were excluded if they developed a serious adverse event (SAE) during prior therapy with evolocumab and if they required unblinded adjustment of lipid therapy during the first 12 weeks of the study. The current study included a 52-week control period that compared evolocumab therapy to standard-of-care (SOC) in a 2:1 ratio. Following completion of the 52-week period, the SOC group then transitioned to evolocumab therapy. Follow up lipid evaluation at 1,2,3, and 4 years was available for 92%, 85%, 80%, and 61% of patients respectively.

After 52-weeks of therapy, evolocumab plus SOC was associated with reduction in LDL-C by 61%, compared to 2% with SOC alone (P<0.001). Compared to patient baseline LDL-C levels, there was 59%, 59%, and 57% reduction in LDL-C at 2, 3, and 4 years respectively. SAE occurred in 6.9% of the evolocumab plus SOC arm compared to 6.8% in the SOC alone arm. New onset diabetes (2.8% vs 4.0%), neurocognitive events (0.4% vs. 0.0%), and muscle related events (4.7% vs. 8.5%) did not significantly increase for the evolocumab therapy arm compared with the SOC arm. Non-neutralizing antidrug antibodies developed transiently in 4 patients and then resolved. No neutralizing antidrug antibodies developed during the study.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cholesterolpcsk9
Previous Post

Association between maternal body mass index in early pregnancy and incidence of cerebral palsy

Next Post

Pembrolizumab improves median survival amongst those with recurrent urothelial carcinoma

RelatedReports

Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
Next Post
Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Pembrolizumab improves median survival amongst those with recurrent urothelial carcinoma

Gender conformity influences use of laxatives and muscle-building products

Medical use of prescription opioids linked to nonmedical use in adolescents

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Anakinra not linked to reduction in fatigue severity in women with chronic fatigue syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options